ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1695

Baseline Characteristics and Outcomes in a Retrospective Cohort of Patients with Systemic Sclerosis Related Interstitial Lung Disease

Robert L. Mango1, Eric L. Matteson2, Cynthia S. Crowson3, Jay H. Ryu4 and Ashima Makol2, 1Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, 2Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 4Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: interstitial lung disease, scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is a major contributor to morbidity and mortality in systemic sclerosis (SSc). We sought to identify the distribution of clinical characteristics, comorbidities, pulmonary disease patterns, and outcomes in a retrospective cohort of SSc-ILD.

Methods: A retrospective review of medical records was conducted to identify patients with SSc seen at a single tertiary referral center in 2000-2013 within 1 year of ILD diagnosis. All patients met the 2013 ACR/EULAR classification criteria for SSc. Patients were included only if at least 1 year of follow up data was available. Baseline demographics, comorbidities and clinical characteristics were collected, in addition to pulmonary function tests, lung imaging, and echocardiogram for 3 years after ILD diagnosis. Cox models were used to examine associations between potential risk factors and progression or mortality.

Results: A total of 126 patients with SSc-ILD were identified (87 [69%] female; mean age: 57.5, range 31-82 years). Based on high resolution chest CT (or biopsy when available), 108 (86%) were characterized as nonspecific interstitial pneumonia (NSIP), 17 (13%) as usual interstitial pneumonia (UIP), 1 as unclassifiable ILD. Pulmonary hypertension (PHTN) was noted in 44 (35%) at baseline, and this did not differ between ILD subtypes. Patients with UIP were more likely than those with NSIP to have chronic obstructive pulmonary disease (COPD) at baseline (24% vs 5%, p = 0.005). 89% had limited cutaneous SSc, 7% had diffuse cutaneous, and 4% SSc sine scleroderma. SSc specific serologies (i.e., SCL-70, centromere, and/or RNA Pol III) were positive in 56 (46%) patients, somewhat more common in NSIP than UIP (49% vs 25%; p=0.07). Baseline initial forced vital capacity (FVC) and diffusion capacity (DLco) were not significantly different between ILD subtypes. Progression to DLco < 40% predicted or too ill to perform DLco was noted in 39% (95% CI 30% – 48%) by 3 years and did not significantly differ between ILD patterns (p=0.64). Risk factors for progression included baseline DLco (p < 0.001), FVC (p = 0.001) and PHTN (p = 0.002). Only 5 patients progressed to FVC < 50% predicted. During a median of 5.0 years of follow-up, five-year survival was 86% (95% CI 80 – 92%), and was only marginally worse in UIP than NSIP (hazard ratio [HR]: 2.0; p=0.057). Risk factors for mortality included comorbid COPD, hypertension and those identified for progression. The presence of inflammatory arthritis at baseline (16 patients, 13%) appeared to be a good prognostic indicator for mortality (HR 0.21, 95% CI 0.05 – 0.89).

Conclusion: Outcomes were overall somewhat better in SSc-ILD compared with those described in idiopathic pulmonary fibrosis, consistent with previous studies of connective tissue disease related ILD. ILD subtype had marginal prognostic significance in this cohort of patients with SSc-ILD. Baseline FVC and DLco, comorbid COPD, hypertension, and pulmonary hypertension at any time were risk factors for a poor prognosis. These findings highlight the importance of a thorough baseline pulmonary evaluation in predicting outcomes in patients with SSc-ILD.


Disclosure: R. L. Mango, None; E. L. Matteson, None; C. S. Crowson, None; J. H. Ryu, None; A. Makol, None.

To cite this abstract in AMA style:

Mango RL, Matteson EL, Crowson CS, Ryu JH, Makol A. Baseline Characteristics and Outcomes in a Retrospective Cohort of Patients with Systemic Sclerosis Related Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/baseline-characteristics-and-outcomes-in-a-retrospective-cohort-of-patients-with-systemic-sclerosis-related-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-characteristics-and-outcomes-in-a-retrospective-cohort-of-patients-with-systemic-sclerosis-related-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology